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Summary 
We report the isolation of a panel of CD4 + T  helper type 1 autoreactive T  cell clones from 
the spleen of unprimed nonobese diabetic mice, a murine model of human insulin-dependent 
diabetes mellitus. The T cell clones express a diverse repertoire of T cell receptors, three of which 
recognize/3 islet cell autoantigen(s). The islet cell-reactive T cell clones inhibit adoptive transfer 
of insulin-dependent diabetes mellitus and intraislet lymphocytic infiltration. The protective ca- 
pacity of the T  cell clones correlates with their ability to produce a novel immunoregulatory 
activity that potently inhibits in vitro allogeneic mixed lymphocyte reaction. The partially purified 
activity significantly inhibited the adoptive transfer of diabetes.  Our work provides evidence in 
support of the existence of T  helper type 1, CD4 + T cells reactive to/3 islet cell autoantigens 
that have acquired a protective instead of a diabetogenic effector function. These T cells mediate 
their protective action in part by production of an immunoregulatory activity capable of down- 
regulating immune responses, and they are likely to represent a population of regulatory T cells 
that normally plays a role in maintaining peripheral tolerance. 
I 
nsulin-dependent diabetes mellitus (IDDM) t is a result of 
autoimmune destruction of the insulin-producing pancreatic 
/3 islet cells (for review see reference 1). The/3 islet autoantigen- 
specific T cells are implicated to play a key role in the patho- 
genesis of IDDM (2-6). Susceptibility to IDDM in humans 
and in nonobese diabetic (NOD) mice is strongly associated 
with expression of MHC class II/3 chain that lacks the usual 
acidic aspartate residue at position 57 (Asp-57) (for review 
see reference 7). Expression of transgenic class II/3 chain con- 
taining the Asp-57 protected the NOD mice from sponta- 
neous development of IDDM (8-12).  Clonal deletion or func- 
tional silencing of/3 islet autoantigen-specific diabetogenic 
T cells has been proposed as the mechanism whereby these 
molecules provide protection (4). However, it is now evident 
that protection by MHC class II is not mediated by these 
mechanisms (9,  13,  14). Since splenic T cells isolated from 
NOD mice expressing the protective Aa  a transgene have the 
capacity to inhibit adoptive transfer of IDDM, it has been 
t Abbreviations used in this paper: AMLK, autologous mixed lymphocyte 
reaction; IDDM, insulin-dependent  diabetes mellitus; LPS-blast, LPS- 
activated splenic blast; MLK, mixed  lymphocyte  reaction; NOD, nono- 
bese diabetic; SN, supernatant; TCGF, T cell growth factor. 
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suggested that the mechanism whereby protective MHC class 
II molecules protect mice from diabetes includes selection in 
the thymus and/or induction in the periphery T cells capable 
of suppressing diabetes development (15). 
The nature of T cells capable of suppressing autoimmune 
diabetes is at present poorly understood. Boitard et al. have 
demonstrated the presence of such T cells in the CD4 § , but 
not  CD8 +,  compartment  of spleen  cells  from  8-wk-old 
NOD mice (16). T cell clones capable of suppressing IDDM 
have been isolated by various laboratories (17-20). These T 
cell clones appear to exhibit properties that are quite different 
one from another, indicating that  a diverse population  of 
regulatory T cells may be involved in maintaining peripheral 
tolerance. At present,  the repertoire of regulatory T  cells 
capable of inhibiting IDDM, their requirements for activa- 
tion, their cellular targets, T cell receptor diversity, and their 
molecular basis  for protection are poorly understood. 
We report here the isolation and characterization of three 
/3 islet cell-reactive T  cell clones that suppress  the develop- 
ment of IDDM. These islet cell-reactive T cells, which have 
acquired a protective instead of a diabetogenic effector func- 
tion, may represent part of a regulatory network of T cells 
that normally play a role in maintaining peripheral tolerance. 
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Micg Cell Lines, Antibodies, and Peptides.  Mice were purchased 
from Taconic Farms, Inc. (Germantown, NY). NOD/Lt mice were 
bred at the animal facility at Dana-Farber Cancer Institute (Boston, 
MA). The following mAbs were used: anti-I-A  k' r. s. ~ g7 (10-2.16, 
[21]); anti-I-A  a (MK-D6, [22]), anti-Ib4 (11b11, [23]); anti-IL-2 
receptor (PC 61 5.3; TIB-222; American Type Culture CoLlection, 
RockviLle, MD); anti-V~2 (B20.6, [24]);  anti-V/~8 (F23.1,  [25]); 
and anti-VB14 (14-2, [26]). The peptides used, Pl (yTYTVHAA- 
HAYTYt; small letters denote D amino acids) and P2 (KMKMVH- 
AAHAKMKM) (27), were synthesized at Dana-Farber Cancer In- 
stitute core facility. 
Generation and Maintenance  of  Autoreactive T Cell Clones.  T celt 
clones were derived from unprimed 4-wbold female NOD mice 
purchased from Taconic Farms, Inc. Splenic lymphocytes were cul- 
tured in a U-bottomed 96-weLl plate (5  x  10Vwell). T cell clones 
NOD-2, NOD-5, NOD-6, and NOD-12 were generated in DMEM 
supplemented with 10% FCS and 4 U/m1 of partially purified rat 
IL-2 (T cell growth factor [TCGF], Collaborative Research, Inc., 
Lexington, MA), whereas clones NOD-14 and NOD-21 were es- 
tablished in  FCS-free DMEM  supplemented with 0.5%  NOD 
serum and 4 U/m1 recombinant mouse IL-2 (Genzyme Corp., Cam- 
bridge, MA) during the first 2 wk of culture. Surviving T  ceils 
were harvested I wk later by Ficoll centrifugation, and they were 
expanded in flat-bottomed 96-well plate using the same culture 
medium. I wk later, the surviving T cells were restimulated with 
NOD spleen  cells using the same culture medium but without 
IL-2 supplementation. After 4 d of selection in ID2-free medium, 
surviving T ceUs were pooled and were cloned by limiting dilution 
in culture medium supplemented with 10% FCS and 4 U/ml of 
rat TCGF and in the presence of freshly isolated irradiated NOD 
spleen cells (1  x  104 APC/U-bottomed well).  T cell clones thus 
generated were maintained in the T cell medium supplemented with 
varying concentrations of rat TCGF (4-25 U/ml). They were re- 
stimulated with NOD spleen  cells at intervals of 2-3 wk. 
Proliferation  Assays.  Proliferation ofT cells was measured as in- 
corporation of [3H]thymidine by the indicated number of T cells 
for 16-20 h after the specified period of stimulation with irradiated 
(2,000 tad) APC in the presence or absence of appropriate concen- 
trations of antigens, and in the absence of added IL-2. LPS-activated 
splenic blast (LPS-blast)  APC used for FCS-free activation were 
prepared from spleen cells depleted of T  cells by two rounds of 
incubation with saturating concentrations of purified mAbs specific 
for Thy-l.2, CD4,  and CD8,  followed by complement lysis, all 
in FCS-free DME. The T cell-depleted spleen cells were cultured 
for 48 h in FCS-free DME supplemented with 0.5% NOD serum 
and LPS (10 #g/m1). The resultant blasts were washed twice with 
PBS before use as APC in a proliferation assay. FCS-free mouse 
IL-2 was prepared from 24-h culture supernatant of NOD spleen 
cells stimulated with Con A (5 #g/ml) in RPMI  1640 medium 
supplemented with only 0.5% NOD serum, and partially purified 
by NH4SO4 precipitation and extensive dialysis with PBS. Pan- 
creatic ~  islets  were isolated from NOD  mice according to the 
method ofBrunstedt et al. (28) using FCS-free DME medium sup- 
plemented with 0.5% NOD serum. The islets were digested to 
single cells in serum-free DME containing trypsin (0.05% wt/vol) 
and DNase (2 #g/ml) for 30 rain at 37~  with agitation. The islet 
cells were cultured for 24 h in FCS-free DME/0.5% NOD serum 
before use. 
Assay for Cytokine Production.  The Ib2 content of culture su- 
pernatants was determined by bioassay using the IL-2-dependent 
CTLb20 cell line (29) in the presence and absence  of anti-Ib2 
receptor (PC61 5.3) and anti-IL-4 (11Bll) mAbs (1:10 dilution of 
hybridoma culture supernatants). 1 U oflb2 is defined as the con- 
centration that supports half-maximal proliferation of CTLL-20 cells. 
The Ib4, IFN-"/, and TNF-o~ concentrations were determined by 
ELISA assay. All of the antibodies used in the assays were purchased 
from PharMingen (San Diego, CA), and the assays were performed 
according to the manufacturer's protocol. The recombinant IL-4 
(Schering-Plough, Kenilworth, NJ), IFN-"/(Amgen Bidogicals, 
Thousand Oaks, CA), and TNF-ce (Genzyme Corp.) were used 
as standards  for ELISA assays. 
AUogeneic Mixed Lymphocyte Reaction (MLR).  The following 
procedure was routinely performed unless otherwise indicated. 5 x 
10  s nylon wool-purified NOD splenic T  cells (responders)  were 
cocultured with  5  x  10  s irradiated (2,000 tad)  unfractionated 
spleen cells from DBA/2 mice (stimulators), in the presence or ab- 
sence of appropriate concentrations of various test reagents, for 
116 h. Proliferation of responder T cells was then measured as in- 
corporation of [3H]thymidine during the last  20 h of culture. 
Cloning and Sequencing of TCR mRNAs.  The TCK ce and 
chain cDNA molecules were cloned and sequenced  by anchored 
PCR as described  previously (30). 
Adoptive Transfer  of Diabetes.  8-wk-old male or female NOD 
mice were irradiated (775 tad). Within 2 h, the mice were injected 
intravenously with pooled splenocytes  (1-2  x  107) derived from 
newly diabetic female NOD/Lt mice suspended in 400 #1 of sterile 
PBS. For cotransfer with T  cell clones,  mice were injected with 
a  mixture  of appropriate  T  cells  (1  x  107) and  diabetogenic 
splenocytes  (1-2  x  107) suspended  together in 400 #1 of PBS. 
Animals were kept in pathogen-free conditions. Urine was tested 
for glucose (Keto-Diastix; Miles, Inc., Kankakee, IL), and glyco- 
suric mice were checked for fasting serum glucose (Chemstrip bG, 
Accu-check III; Boehringer Mannheim Corp., Indianapolis,  IN). 
Diabetes was diagnosed when permanent fasting glyeemia >2.5 g/ 
liter occurred. 
Histology.  Recipient mice were killed  21 d  after spleen  cell 
transfer.  Pancreata were excised, fixed in buffered 10% formalin, 
and processed for paraffin sectioning. Tissue sections (5 #m) were 
stained with hematoxylin and eosin and microscopically evaluated 
for the presence of insulitis by using the following classification: 
0, islet devoid of lymphocytic infiltration; 1, inflammatory mono- 
nuclear cells located peripheral to the islet; 2, mild insulitis, <25% 
of the islet interior contains lymphocytic inflammatory cells; 3, 
moderate insulitis, 25-50% of the interior of the islet contains lym- 
phocytes;  4,  severe insulitis,  50-100%  of the  islet  interior  is 
infiltrated; ES, end-stage islets devoid of~ ceUs and associated lym- 
phocytic infiltrate.  All islets contained in two noncontiguous sec- 
tions of the pancreas  were examined and scored individually. 
Results 
Cellular Characteristics of  Isolated Autoreactive T Cell Clones. 
Our panel of T  cell dories was isolated from the spleen of 
unprimed 4-wk-old female NOD mice by a procedure that 
selects for growth of T  cells reactive to syngeneic APC. The 
detailed procedure for generation of the clones is described 
in Materials and Methods. The T cell clones thus established 
responded routinely to irradiated (2,000 tad) NOD  spleen 
cells in medium containing 10% FCS in the absence of I1-2. 
Indirect immunofluorescence staining using appropriate mAbs 
88  CD4+-protective T Cell Clones from Nonobese Diabetic Mice Table  1.  Autoreactive  T  Cell  Clones Respond  to Syngeneic APC in an I-A~7-restn'cted Manner 
[3H]thymidine incorporation (cpm) 
Spleen cells (+ 10%  FCS) 
Stimulator 
cells  BALB/c  NOD  BALB/c  NOD 
LPS-blasts (FCS-ffee) 
NOD  +  10-2.16  NOD  +  MK-D6 
NOD-5  413  _+  120  36,920 -+  2,266  1,866 _+  205  39,540 _+  1,603  3,100  _+  428  31,236  _+  3,300 
NOD-6  2,796  +_  731  26,660 _+  4,992  1,536 _+  32  15,090  _+  1,199  2,130  _+  330  16,020  +  2,065 
NOD-14  190  _+  70  12,220  _+  2,163  776  _+  31  9,560  _+  1,361  850  _+  78  10,670  _+  629 
NOD-21  1,253 _+  119  92,686 _+  5,435  1,950 _+  100  38,700 _+  4,937  10,030 _+  5,635  45,500  _+  8,122 
NOD-2  1,056  _+  261  80,386 -+ 9,720  1,110 _+  135  1,576  _+  150 
NOD-12  630  _+  88  74,400  _+  3,497  586  +  145  876  +  138 
5 x  10  4 T cells were incubated with 5 x  10  s irradiated (2,000 rad) spleen or T cell-depleted LPS-blast stimulator  cells (prepared as described in 
Materials and Methods) for 44 h. For FCS-ffee  experiment,  T cells were washed twice in protein-flee  DMEM before assay. For anti-Ia  experiment, 
the stimulators  were preincubated with the appropriate mAb (1:10 dilution  of hybridoma  supernatant) for 30 min at 4~  before  assay. The cultures 
were pulsed with 1 #Ci of [3H]thymidine  during the last 20 h of culture. The values shown are means +_  SEM of triplicate cultures. 
showed that  all  the clones were Thy-l.2 +,  CD4+CD8 -, 
and TCR-ol/B + (data not shown). 
All of the T cell clones (NOD-2, -5, -6, -12, -14, and -21) 
proliferated vigorously in response  to irradiated (2,000 tad) 
NOD,  but  not  to  BALB/C,  splenic  APC  in  DME  sup- 
plemented with 10% FCS (Table 1). They responded poorly 
to NOD  splenic  APC in the FCS-free  medium (data not 
shown).  However,  NOD-5,  -6,  -14,  and -21  proliferated 
vigorously in response to stimulation with syngeneic NOD 
but not to BALB/c LPS-blast  APC in FCS-free DME sup- 
plemented with only 0.5% NOD serum (Table 1). In this 
experiment, the T cell clones were washed twice with FCS- 
flee medium before the assay, and the LPS-blasts  were pre- 
pared in the absence  of FCS and in the presence  of 0.5% 
NOD  serum. T  cell clones NOD-2  and NOD-12,  which 
we have subsequently determined to be BSA/I-Ag  7 specific, 
were not activated by syngeneic LPS-blasts  (Table 1). The 
I-AgT-cross-reactive  mAb  10-2.16, but  not  the  irrelevant 
MK-D6 mAb (I-A  d specific), inhibited the autoreactive re- 
sponses of T cell clones NOD-5, -6, -14, and -21 (Table 1). 
We conclude from data presented in Table 1 that NOD-5, 
-6, -14, and -21 are I-A~7-restricted autoreactive T cell clones 
because  they can proliferate in response to syngeneic LPS- 
blast APC in the absence of added foreign antigens, and that 
this response is inhibited by anti-I-As  7 mAb. 
T  cell clones NOD-2 and NOD-12  are not autoreactive 
but  are  BSA/I-Ag  7 specific, because  they proliferated in a 
dose-dependent manner to BSA plus NOD splenic APC, and 
the responses were inhibited by the anti-I-AgT-cross-reactive 
10-2.16 mAb (data not shown). In a similar assay, T cell done, 
NOD-5, -6, -14, and -21 did not respond to BSA (data not 
shown). Since the ABBOS BSA peptide sequence (position 
152-168) has been implicated as a possible trigger of human 
IDDM (31), we tested NOD-2 and NOD-12 for reactivity 
to ABBOS peptide. We observed  that neither NOD-2 nor 
NOD-12 was reactive  to ABBOS/I-Ag  7 (data not shown). 
The lymphokine production profile of the T  cell clones 
is shown in Table 2. Upon activation, T cell clones NOD-2, 
-5, -12, -14, and -21 showed enhancement of I1,2 and IFN-3~ 
production but not 11,4. The NOD-2, -12, -14, and -21 T 
cell clones also produced TNF-ol. Cross-reactivity of the an- 
timurine TNF-cz mAb pairs, used in the TNF-ot ELISA assay, 
with TNF-~ is not known (PharMingen technical informa- 
tion). Clone NOD-6  showed increased  production of I1,4 
but not of IL-2, IFN-% and TNF-ol. Thus, NOD-6 belongs 
to the Th2 and the other T  cell clones to the Thl subset 
of T  cells (32). 
Specific Self Peptides A re Required for Activation of Autoreac- 
tire T  Cell Clones.  We next asked whether specific self pep- 
tides are required for autoreactive responses  of NOD-5, -6, 
-14, and -21. We approached this question by examining the 
effect ofpeptide Pl on activation of our pand of autoreactive 
T cell dones. Peptide Pl (.yTYTVHAAHAYTYt; small letters 
denote D  amino acids) has been reported to bind I-As  7 and 
to block antigen presentation by I-As  7 (27).  We observed 
that peptide P1 inhibited the autoreactive responses of NOD-5, 
-6,  -14, and -21 T  cell dones in a dose-dependent manner 
(Fig. 1). Peptide Pl also inhibited the BSA-specific responses 
of NOD-2 and 12 T cell clones, which were included as posi- 
tive controls (Fig. 1). The inhibition was specific, since similar 
concentrations of peptide P2 (KMKMVHAAHAKMKM), 
which binds I-A  a but not I-As  7 (27),  had no effect on the 
proliferative  responses (Fig.  1). We conclude, therefore, that 
presentation of specific sdf peptides present on LPS-blasts 
by I-As7 is required for autoreactive responses  of NOD-5, 
-6,  -14, and -21 T  cell clones. 
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Figure 1.  Selective inhibition  of autoreac- 
tive and BSA-specific  proliferative  responses  of 
NOD T cell clones by peptide P1 that binds 
l-Ag  7 (closed  circles) and not by peptide P2 that 
binds I-A  d but not I-As7 (open circles). LPS- 
activated  NOD spleen  cell APCs (A-D) or un- 
activated NOD spleen cells (E, F) were prein- 
cubated for 24 h with the indicated concen- 
trations of peptide P1 or P2 in FCS-free  DME 
supplemented with 0.5% NOD serum before 
irradiation (2,000 rad) and use as stimulators. 
T cell clones (5  x  104) were cocuhured for 
24 h  with  the pretreated stimulators (5  x 
10  s) in the presence of the indicated concen- 
trations  of peptide  P1  or  P2  in  FCS-free 
DME/0.5%  NOD serum medium, and, for 
E and F, in the presence of BSA (1 mg/ml). 
The cultures were pulsed with [3H]thymidine 
(1 #Ci/culture) and harvested  20 h later. 100% 
proliferation denotes [3H]thymidine incorpo- 
ration of activated T cells in the absence of Pl or P2. 0% proliferation was background proliferation of T cells stimulated with BALB/c LPS-blasts 
(A-D) or NOD spleen cells in the absence of added BSA (E, F). The values for 0% and 100% for A-F were: 2,603  +_  228 and 30,063  _+  4,088 
(.4); 1,020 _+  271 and 10,136 _+  1,024 (B); 63  _+  32 and 14,866  _+  1,230 (C); 875  _+  219 and 11,613 _+  360 (D); 895  _+  147 and 32,266  _+  2,967 
(E);  and 1,160 _+  1,018 and 24,870  _+  3,521 (F). Values shown are means  _+  SEM of triplicate experiments. 
Three Autoreactive  T Cell Clones Are Reactive to ~  Islet Cell 
Antigen(s).  We tested our panel of autoreactive T cell clones 
for reactivity to autoantigens present on NOD  pancreatic/~ 
islet cells. Activation of T  cell clones by NOD  splenic APC 
in the presence or absence of NOD  islet cells was assessed 
in FCS-free DME  supplemented with 0.5%  NOD  serum. 
Fig. 2  shows that NOD-5,  -6, -14, and -21 were not signi- 
ficantly activated by NOD  splenic APC alone in the FCS- 
free  DME/0.5%  NOD  serum  medium.  The  addition  of 
10,000 irradiated (2,000 rad) NOD/~  islet cells to 5  x  10  s 
NOD  splenic  APC  resulted  in  enhanced  proliferation of 
NOD-5, -14, and -21 T  cell clones. The autoreactive NOD-6 
T  cell clone,  which  is  similar to  NOD-5,  -14,  and  -21  in 
its responsiveness to LPS-blasts, is not activated by the pres- 
ence of islet cells. 
T Cell Receptor Diversity ofAutoreactive  T Cell Clones.  The 
repertoire of TCRs expressed by the T  cell clones was deter- 
mined.  The TCR-c~ and -B cDNAs were amplified by an- 
chored PCR  and subcloned into a plasmid vector, and the 
V/J junctional cDNA sequences were determined. The se- 
quences of the in-frame a  and/3 chain V/J junctional CDR-3 
region are presented in Fig. 3, A  and B~ The surface V~ ex- 
pression was confirmed by indirect immunofluorescence using 
the VB2-, VflS-, and Vfl14-specific mAbs B20.6, F23.1, and 
14-2, respectively. Two of the T cell clones express TCR V/~8.1 
region (NOD-14 and NOD-21), and two express TCR Vc~4 
region (NOD-6 and NOD-14); otherwise, the Vc~, V/~, Jo~, 
andJB segment usage was diverse, and there was neither ap- 
parent sequence identity nor selection for particular amino 
acid residues in the V/J junctional region. 
Table 2.  Lymphokine Production by NOD  T  Cell Clones 
T  cell 
clones  IL-2  IL-4  IFN-'y  TNF 
U/ml  U/ml  U/ml  pg/ml 
NOD-5  3.0  +  0.1  <10.0  86.0  _+  4.9  <30.0 
NOD-6  <0.5  158.0  _+  3.2  <8.0  <30.0 
NOD-14  2,704.0  +  40.0  <10.0  307.0  _+  14.0  2,496.0  +  65.0 
NOD-21  8.1  +  0.1  <10.0  315.0  _+  11.0  1,243.0  _+  124.0 
NOD-2  26.0  +  7.0  <10.0  219.0  +  11.2  2,237.0  +  81.0 
NOD-12  7.7  +  2.6  <10.0  275.0  _+  12.5  948.0  _+  157.0 
5  x  10  s T cells were cultured in the presence and absence of 5  x  106 irradiated (2,000 rad) NOD spleen cells in 1.0 ml cultures. The differences 
in lymphokine contents of supernatants harvested from 24-h culture of stimulated and unstimulated T cell clones were determined as described in 
Materials and Methods.  Values shown are means  _+  SEM of triplicate assays. 
90  CD4+-protective  T Cell Clones from Nonobese Diabetic Mice Figure  2.  T cell clones NOD-5, -14, and -21 are reactive to/3 islet cell 
antigen(s).  T  cells  (5  x  104) were cocultured  for  44 h  with irradiated 
BALB/c  or  NOD  spleen  cells  (5  x  105) in  FCS-free  medium sup- 
plemented with 0.5% NOD serum in the presence or absence of NOD 
/3  islet  cells  (10,000  cells)  or  10%  FCS.  The  cells  were  pulsed  with 
[3H]thymidine (1  t~Ci/cuhure)  during the last  20  h  of culture.  Values 
shown are means  -+  SEM  of triplicate  experiments. 
t8 Islet Cell-reactive  Autoreactive T Cell Clones  Suppressed  De- 
velopment oflDDM.  To examine the effect of NOD-5 (islet 
reactive) on spontaneous development of diabetes,  we injected 
1  ￿  107 NOD-5  T  cells into 4-wk-old unirradiated female 
NOD  mice  housed  in  open  cages.  They  were  suitable  as 
recipients because, at 4 wk of age, pancreatic histology showed 
these mice  to be free of intraislet  lymphocytic  infiltration; 
hyperglycemia does not develop until after 4 mo of age when 
kept  at  our  animal  facility.  Diabetes  developed  at  age 6-7 
mo in 66%  of control unmanipulated animals, and in 75% 
of mice when  given  a single  injection  of 1  x  107 control 
nylon  wool-purified  splenic  T  cells  from  4-wk-old  female 
NOD  mice.  By  contrast,  a single intraperitoneal  injection 
of 1  x  107 NOD-5  T  cells into 4owk-old NOD  mice com- 
pletely protected the mice from diabetes for the entire 12 mo 
of observation  (Fig.  4  A). 
The  adoptive  transfer  procedure  is  widely  accepted  as  a 
valid method  for rapid  assessment  of insulitis  and diabetes 
in recipient mice (37). We used this protocol for subsequent 
testing of T  cell clones in vivo. Fig.  4 B  shows that all con- 
trol mice receiving  1  x  107 diabetogenic donor spleen cells 
alone developed overt diabetes within 3 to 4 wk of transfer. 
In experiment 1, mice receiving a cotransfer of the Thl islet- 
reactive NOD-5, NOD-14, or NOD-21 T cell clones remained 
normoglycemic in the 21-d period of observation before the 
killing of the animals for pancreatic  histology.  In contrast, 
the  Th2  autoreactive  NOD-6  and  the  Thl  BSA/I-A gT- 
specific  NOD-2 and NOD-12 T cell clones were not protec- 
tive.  In  a  second  experiment,  we  observed  that  NOD-5, 
NOD-14,  and NOD-21  T  cell clones significantly inhibited 
adoptive  transfer  of diabetes  for at  least  an 8-wk  period. 
To control for the possibility that BSA-specific  T cell clones 
would not be activated in vivo because of the absence of an- 
tigen,  we performed an additional experiment whereby the 
BSA-specific NOD-2 cotransferred mice were given a twice- 
a-week injection of 1 mg BSA per mouse (Fig. 4 B, NOD-2 
Expt. 2).  Injection of BSA had no effect  on the kinetics  of 
development  of diabetes. 
Protective T Cell Clones Inhibited Lymphocytic Infiltration of 
Pancreatic Islets.  The pancreatic islets of recipient mice, ob- 
A 
CLONE 
NOD-5  Vc(10 
NOD-6  Vc~4 
NOD-14  Va4 
NOD-21  Vc~l 
B 
CLONE 
NOD-5  V~B14 
NOD-6  V[B2 
NOD-t4  V~8.1 
NOD.21  V~8,1 
v  N 
LCAAN~ 
CTC  TGT  GCT  OCT  ATG  GG  G 
YCALS  GE 
TAC  TGT  GCT  CTG  AGT  G  GG  GAG 
YCALS  DLG 
TAC  TGC  GCT  CTG  AGT  G  AT  CTG  GG 
FCAAS  SR 
TTC  TGC  GCA  GCA  AGC  AGT  AGA 
V  N 
L  C  A  W  S  F  A 
CTC  TGT  GCC  TGG  AGT  TTC  GCC 
C  T  C  S  A  E 
TGC  ACC  TGC  AGT  G  CA  GAA  C 
F  [  A  S  R 
TTC  TGI  GCC  AGC  AG 
F  C  A  S  S  0  [ 
TTC  TGT  GCC  AGC  AGT  GAT  Ar 
J 
D  R  G  S  A 
GAT  AGA  GGT  TCA GCC  J~[LB2 
N  M  G  Y  K 
AAC  ATG  GGC  TAC  AAA  J~TA19 
G  G  S  g  N 
T  GGG  GGC  AGT  GGC  AAC  Jo.TT11 
N  Y  G  N  E 
AAC  TAT  GGA  AAT  GAG  ,JaTA3| 
D  N  J 
GTGG  DERLF 
GG~ ACA BGG GGC  g  AC GAA AGA TTA TTT  J~1-4 
R  R  OTOYF 
GG  A  GG  GAC  ACC  CAG  TAC  TTT  J~2-5 
DRG  y~OYF 
G  ~AC  AGG  GG  C  TAT  GGA  CAG  TAC  TTC  d~2-7 
GC  OOAEO 
T  GGG  GGG  G  AC  GAT  GCT  GAG  CAG  J~2-1 
Figure  3.  Nucleotide and predicted amino 
acid sequences of the  junctional regions of TCK 
ot chain  (A) and/3 chain  (B)  of autoreactive 
T  cell clones  NOD-5,  -6, -14 and -21. These 
sequence data are available from EMBL/Gen- 
Bank/DDBJ under accession numbers U27223- 
U27230. The assignment of V/3junctions was 
based on homology comparison  of the deter- 
mined cDNA sequences with the germline se- 
quences  for  V/314  (33)  and  V/38.1/V38.2/ 
V/38.3  (34),  and deduced  for NOD-6  (V/32) 
by comparison  with mRNA sequences avail- 
able for V/32 from GenBank. The assignment 
of D/3 and J/3 nucleotide  sequences was based 
on comparison  of the determined  sequences 
with the published germline D/31.1/D/32.1  and 
germline J/3 sequences  (35,  36).  The assign- 
ment for the Va junctions was deduced from 
comparison  of the determined sequences with 
all GenBank mRNA sequences available  for the 
particular Vc~ family. The nomenclature  and 
assignment  of  Jot sequences were based on the 
germline TCR ot and b chain locus  available 
from GenBank  (MUSTCRA,  accession number 
M64239). 
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Figure 4.  Theeffectofinvivoinoc- 
ulation autoreactive T cell clones on de- 
velopment  of IDDM.  (A)  Effect of 
NOD-5 T cell clone on spontaneous  de- 
velopment of  diabetes  when injected  into 
young mice. 4-wk-old unirradiated fe- 
male NOD mice were given a single 
intraperitoneal injection  of I  x  107 re- 
sting and pathogen-f~e NOD-5 T cells 
(open circles). Control animals received 
either no T cell  injection (closed  d~monds) 
or injection of I  x  10  7 nylon wool- 
purified splenic T cells from 4-wk-old 
female NOD mice (open squares). Ani- 
mals were kept in open cages  and were 
monitored for onset of diabetes. (B) Ef- 
fect of cotransfer of NOD T cell clones 
on adoptive transfer of diabetes. 8-wk- 
old female or male NOD mice were 
irradiated (775 rad) 2--4 h before intra- 
venous injection of 1 x  10  7 uRfraction- 
ated pooled spleen cells from newly dia- 
betic female  NOD/Lt mice, with (closed 
squares) or without (open squares) co- 
transfer of 1 x  10  7 NOD T cell clones 
that had been activated with syngeneic 
spleen  cells 2 wk before the experiment. 
Animals  were kept in pathogen-free  con- 
dition and were monitored for onset of 
diabetes at the indicated intervals. 
tained 3 wk after adoptive transfer, were scored for severity 
of insulitis  according  to  a  standard  grading  system  (see 
Materials and Methods). Table 3 shows the effect of cotransfer 
of the T  cell clones on development  of insulitis.  All of the 
islets of mice receiving donor diabetic spleen cells alone ex- 
hibited an advanced  degree of insulitis (grade 3, 4, and end 
stage as described in Materials  and Methods).  By contrast, 
most  (>70%)  of  the  islets  in  NOD-5,  NOD-14,  and 
NOD-21 coinjected animals were normal or lightly infiltrated 
in the periphery (grade 0, 1, and 2). Nonprotective autoreac- 
tive NOD-6 and BSA/I-AgT-specific NOD-12 T cell clones 
did not prevent  lymphocytic infiltration of/3 islets, because 
>75%  of the islets examined showed severe insulitis (grade 
3  and 4). 
Protective T Cell Clones Secrete an Activity That Inhibits In 
Vitro Allogeneic MLR.  IL-2-free culture supernatants  (SN) 
were generated  as follows. The T cell clones (1  x  106) were 
activated with 5  x  106 irradiated (2,000 tad) NOD splenic 
92  CD4+-protective  T  Cell Clones from  Nonobese Diabetic Mice Table  3.  Effect of Cotransfer of T  Cell Clones on Adoptive  Transfer of Insulitis 
Number  Histological grades  Total 
of  number 
Treatment  mice  0  1  2  3  4  ES  of islets 
Percentage of islets 
Experiment  1 
Donor spleen  alone  2  0  0  0  6  25  69  16 
+  Control T  cells*  2  0  0  0  45  23  32  31 
+  NOD-5  2  38  26  12  10  14  0  81 
+  NOD-12  2  16  0  3  34  41  6  32 
Experiment  2 
Donor spleen  alone  4  0  0  0  0  31  68  74 
+  NOD-5  4  57  24  6  7  3  4  158 
+  NOD-12  4  0  0  0  1  45  53  82 
Experiment 3 
Donor spleen  alone  4  0  0  3  11  54  32  74 
+  NOD-14  4  35  19  16  19  6  5  113 
+  NOD-21  4  60  24  7  5  0  5  104 
Experiment  4 
Donor spleen  alone  4  0  0  3  9  66  22  32 
+  NOD-6  4  0  1  1  21  67  11  101 
8-wk-old male and female NOD mice were irradiated (775 red) and received an intravenous injection of 1  x  107 spleen cells pooled from newly 
diabetic female NOD mice with or without a coinjection of I  x  107 of appropriate T cell clones. Mice were killed 3 wk after cell transfers and 
pancreatic sections were examined and individual islets were graded for degree of insulitis. Grade 0, islet devoid of lymphocytic infiltration; 1, inflam- 
matory mononuclear cells located peripheral to the islet; 2, mild insulitis, <25% of the islet interior contains lymphocytic inflammatory cells; 3, 
moderate insulitis, 25-50% of the interior of islet contains lymphocytes; 4, severe insulitis, 50-100% of the islet interior is infiltrated; ES, end stage 
islets devoid of/3 cells and associated lymphocytic infiltrate. 
* Control  T cells are nylon wool-purified splenic T cells derived from 4-wk-old female NOD mice. 
APC in 1 ml of DME supplemented with  10%  FCS. 48 h 
later,  the activated T  cells were separated  from dead APC 
by Ficoll density centrifugation.  They were incubated at a 
density  of 1  ￿  106/ml  for another  24  h  in DMEM  sup- 
plemented with 10% FCS without added IL-2. We have de- 
termined in a separate time course experiment that our panel 
ofT cell clones produced Ib2 only during the first 24 h after 
activation. Thus, SN collected between 48 and 72 h after ac- 
tivation contained an insignificant amount of II.-2. The seri- 
ally diluted SN were assayed for their ability to inhibit  al- 
logeneic MLK. 
We observed a dose-dependent inhibition of aUogeneic MLR 
by NOD-5,  NOD-14,  and NOD-21 SN (Fig.  5).  SN har- 
vested  from  similarly  activated  nonprotective  autoreactive 
NOD-6 or BSA-specific NOD-2 and NOD-12 T  cell clones 
were inactive (Fig.  5).  The NOD-5 SN is the most potent 
of the three SN in inhibiting allo-MLK, followed by NOD-21 
SN and then NOD-14 SN. This order of relative potencies 
of culture supernatants correlated with the protective capaci- 
ties of the respective T  cell clones;  that is,  NOD-5 is  the 
most  protective  of the  three,  followed  by  NOD-21  and 
NOD-14. 
160- 
140 - 
.r 
~m  120" 
~  80 
-~  60 
~  40. 
20 
0 
.1  1  10  100 
Volume of Culture Supematant Added 
(% assay medium) 
Figure 5.  Protective T cell clones secrete an activity that inhibits allo- 
geneic MLK. Culture supernatant harvested from culture of the indicated 
T cell clones, prepared as described in Results, were serially diluted. 50 ttl 
of the diluted samples were added to a standard allogeneic MLK assay 
described in Materials and Methods. The cultures were pulsed 96 h later 
with [3H]thymidine  (1 #Ci/cultnre) for 20 h. Values shown are means _+ 
SEM of triplicate cultures. 
93  Akhtar et al. We have examined NOD-5  SN for possible contamina- 
tion by pathogens that could cause nonspecific growth inhi- 
bition. Several batches of active NOD-5 SN have been deter- 
mined to be free of endotoxin (limulus amebocyte lysate test 
was performed by Associates of Cape Cod, Inc., Woods Hole, 
MA), and bacteria (culture supernatant was tested by Dana- 
Farber Cancer Institute hospital microbiology laboratory). 
We have also verified that NOD-5 T  cell clone cultured in 
antibiotic-free medium  for >28  d  is  free of mycoplasma 
(mycoplasma test kit,  Gibco BRL,  Gaithersburg,  MD). 
Partially Purified Inhibitory Activity Suppressed Adoptive Transfer 
of IDDM.  We next  examined the effect of the partially 
purified allogeneic MLR inhibitory activity, produced by the 
protective NOD-5 T cell done, on adoptive transfer of IDDM 
in NOD mice. The Ib2-free SN prepared as described for 
Fig.  5 were partially purified to (a) concentrate them into 
a smaller volume suitable for injections, and (b) remove other 
cytokines, such as TNF, IFN-% TGF-jS, and IL-10. The cul- 
ture SN were concentrated by precipitation with ammonium 
sulphate  solution  (50%  saturated).  The precipitates  were 
resuspended in one-hundredth of original volumes of PBS 
and dialyzed extensively against PBS. The dialyzed materials 
were then passed through heparin-Sepharose column (Phar- 
macia Biotech, Inc., Piscataway,  NJ), which does not bind 
the NOD-5 inhibitory factor but binds and removes TNF, 
IFN-% TGF-~, and IL-10 (38-40).  The column eluate was 
the "partially purified SN"  used in  the adoptive  transfer 
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Figure 6.  Partially  purified  NOD-5 culture supernatant  inhibits adop- 
five transfer  of IDDM. 8-wk-old female  or male NOD/Lt mice  were ir- 
radiated (775 rad) 2 h before  intravenous  injection of 2 x  107 unfraction- 
ated pooled spleen cells from newly diabetic  female  NOD/Lt mice, with 
or without cotransfer  of  300/~1 of  partially  purified  NOD-5 SN or NOD- 
12 SN. At weekly  intervals, the recipient  mice received  intravenous  injec- 
tion of the same volume  of partially purified SN. Animals were kept in 
pathogen-free  condition  and were  monitored  at the indicated  intervals  for 
onset of diabetes. 
experiment described below. We have verified that the 100- 
fold concentrated and partially purified SN was '~50-fold 
more potent than the starting material in inhibiting aUogeneic 
MLR (data not shown). 
The partially purified NOD-5  or NOD-12  SN (300  #1 
each), which is equivalent to a starting volume of 3 ml cul- 
ture SN, was coinjected with 2  x  107 donor diabetogenic 
spleen cells intravenously into preirradiated (775 tad) recip- 
ient NOD mice. At weekly intervals, the mice received in- 
travenous injections of the same volume of partially purified 
SN. In two separate experiments, we observed that injection 
of the partially purified NOD-5 SN but not NOD-12 SN 
significantly protected NOD mice from adoptive transfer of 
IDDM (Fig. 6). The degree of protection was not as impres- 
sive as cotransfer of NOD-5 T cell clones as shown in Fig. 
4 B, suggesting that component(s) other than the secreted 
inhibitory factor may play additional roles in the protective 
action of NOD-5. Alternatively, the dose and frequency of 
injection of the partially purified NOD-5 SN may not have 
been optimal for protection. 
Discussion 
Our study was initiated by the hypothesis that autologous 
MLR (AMLR), or syngeneic MLR, which is present in all 
normal individuals,  may represent interactions among T lym- 
phocytes and other immunological cells that regulate immune 
responses  in the absence of foreign antigens. The frequent 
association of impaired AMLR with autoimmune diseases 
in humans (reviewed in 41) and in mice (42) further supports 
the hypothesis that "'AMLR-competent" T cells may Flay a 
role in maintaining peripheral T cell tolerance to self antigens. 
With  this  hypothesis  in  mind,  we  attempted  to  isolate 
"AMLR-competent" T cell clones, which we defined initially 
as T cell clones that are capable of responding to syngeneic 
APC in the absence of added foreign antigens. We chose to 
do this isolation in a relevant autoimmune animal model 
(NOD mouse) that manifested deficient AMLR (43.  44). 
We have succeeded in isolating four "AMLR-competent" 
T cell clones from the spleens of unprimed NOD mice. These 
T cell clones can be activated by stimulation with (a) NOD 
splenic APC in the presence of 10%  FCS;  (b) NOD LPS- 
stimulated splenic blasts in the absence of FCS; and (c) NOD 
splenic APC plus ~/islet cells in the absence of FCS for three 
of the clones. We postulate that LPS-activated B cells and 
macrophages express high levels of self antigens, which are 
required for recognition by autoreactive T  cell clones. FCS 
may be required because it contains factors that activate these 
APC, a possibility that has been discussed by Clayberger et 
al.  (45).  We  have narrowed antigen  specificity of clones 
NOD-5,  -14,  and -21  to self antigens expressed on NOD 
~/islet cells. The islet antigen(s) recognized by these T cell 
clones are likely to be expressed on LPS-blasts  and FCS- 
stimulated APC as well, since these APC are capable of ac- 
tivating the T  cell clones in the absence of islet cells. 
The autoreactive T  cell clones NOD-5,  -6,  -14, and -21 
express TCR bearing V~/14, VB2, V~8.1, and V~8.1 regions, 
respectively. There was no predominant selection for use of 
any particular Vo~ or V~ segment by our panel of autoreac- 
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sociated with preferential usage of a particular V region seg- 
ment. There was no apparent selection for specific amino acid 
residues within the V/J junctional region. The presence of 
selective junctional amino acid usage would have implications 
for a restricted self peptide specificity (46).  The lack of re- 
stricted V  region TC1K sequences suggests the TCR may 
recognize either a diverse set of target antigens or different 
epitopes of a single target antigen.  We need to know the 
selfpeptides recognized by our panel of TCR to discriminate 
between these two possibilities. 
We have  shown that  the 13 islet  cell-reactive NOD-5, 
NOD-14, and NOD-21 T cell clones significantly inhibited 
adoptive transfer of IDDM. The protective capacity of these 
Thl T cell clones is not correlated with production of II,-2, 
TNF, or IFN-3'.  These cytokines are also produced by the 
BSA-specific NOD-2 and NOD-12 T cell clones, which were 
not protective even when BSA was coadministered to the re- 
cipient mice. Depending on the age and route of administra- 
tion, TNF-a  and IFN-y have been reported to exacerbate 
or inhibit IDDM development in NOD mice (47-50). Our 
panel of Thl T  cell clones does not exacerbate disease and 
the BSA-spedfic Thl T cell clones do not inhibit disease. These 
phenomena suggest that the in vivo level of TNF-o~ and IFN-3' 
produced by the inoculated T cell clones may be inadequate 
to affect disease development. The level of TNF-ot and IFN-y 
production may be limited by the concentrations of the ac- 
tivating  autoantigens  available  in  vivo.  ILo2, IFN-3',  and 
TNF-o~ lymphokines are produced by our panel of Thl T 
cell clones only during the first 24 h after activation. In con- 
trast, production of the allo-MLR inhibitory factor by the 
protective T  cell clones persisted for 3 wk after activation 
(Akhtar, I., and K.-N. Tan, manuscript in preparation).  There- 
fore, the in vivo effect of the protective Thl T  cell clones 
is likely to be dominated by the allo-MLR inhibitory factor. 
We have shown that protective capacity of these T cell dones 
correlates with (a) their reactivity to/3 islet cell antigen(s), 
and (b) their production of an activity that potently suppresses 
allogeneic MLIK in vitro. The/3 islet cell reactivity may dic- 
tate the specificity of action of the protective T  cell clones. 
We observed that protective T cell clones inhibited intraislet 
but not periislet lymphocytic infiltration. It is possible  that 
the protective islet-reactive T cell clones may migrate to and 
reside near the islets,  thereby inhibiting intraislet lympho- 
cytic infiltration of diabetogenic lymphocytes. This possibility 
remains to be verified. With regard to production of a factor 
that inhibits allogeneic MLR, our panel of  protective autoreac- 
tive T  cell clones resembles the contemporary definition of 
suppressor T  cells, in that they produce factor(s) capable of 
down-regulating immune responses. The partially purified 
inhibitory activity secreted by NOD-5, which was first de- 
pleted of IL-2, IFN-3', TNF, TGF-13, and IL-10, retained its 
ability to protect mice from adoptive transfer of IDDM. The 
biological and biochemical characteristics of this activity will 
be reported elsewhere (Akhtar, I., and K.-N. Tan, manuscript 
in preparation). Identification of the molecular structure of 
this factor, presently in progress, should allow us to further 
delineate the mechanism of action of this molecule. 
The reason for development of our panel of  protective T  cell 
clones into a Thl lineage is at present unclear. Autoimmu- 
nity is usually attributed to Thl cells, whereas Th2 responses 
are regarded as protective (51). Furthermore, recent observa- 
tions indicate that susceptibility or resistance to spontaneous 
autoimmunity in different strains of mice is influenced by 
a non-MHC-encoded polymorphism that dictates predispo- 
sition of T  cells toward preferential differentiation to Thl 
versus Th2 phenotype, with Th2 being protective and Thl 
pathogenic (52).  Our panel of protective autoreactive T cell 
clones is Thl instead of Th2 and therefore appears  to con- 
tradict these expectations. However, there are other reports 
that disagree with the simple prediction that Thl is patho- 
genic and Th2 is protective. For example, Wogensen et al. 
have shown that transgenic expression of IL-10 in/3 islet cells, 
which promoted a  Th2-1ike lymphokine pattern  of islet- 
infiltrating cells, accelerated the onset of diabetes and increased 
its prevalence. The authors suggested that 13 cell destruction 
in NOD mice may therefore sometimes be a Th2-mediated 
event (53). Additionally, recent observations indicate that the 
inflammatory loci in NOD mice are dominated by a Th2 
cytokine response (54). It is likely that/3 cell destruction and 
T cell suppression of autoimmunity may each involve a more 
complex interplay between Thl and Th2 cells than is cur- 
rently conceived. The respective roles of these subsets may 
vary depending on the stage of the disease and on the site 
of action. Our data provide clear evidence in support of the 
existence of Thl/3 islet cell-reactive T cells that have acquired 
a protective effector function. They mediate their protective 
action in part by production of an activity capable of down- 
modulating immune responses.  We suggest that this type 
of CD4 + autoreactive T  cells may form part of a regulatory 
network of T cells that normally plays a role in maintaining 
peripheral tolerance. 
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